CARDINAL HEALTH INC - 500 Beiträge pro Seite

[Mannerl]

http://www.cardinal.com/content/investor/

[Mannerl]

Cardinal Health Board Of Directors Increases Dividend

DUBLIN, Ohio, May 7, 2003 – The board of directors of Cardinal Health, Inc. (NYSE: CAH), the leading provider of products and services supporting the health care industry, today approved an increase in the company’s dividend and declared the company’s 75th consecutive regular quarterly dividend. The quarterly dividend was increased from $0.025 to $0.03 per common share, without par value, and is payable on July 15, 2003 to shareholders of record on July 1, 2003. Cardinal Health had approximately 446 million shares outstanding as of April 30, 2003.

About Cardinal Health

Cardinal Health, Inc. (www.cardinal.com) is the leading provider of products and services supporting the health care industry. Cardinal Health companies develop, manufacture, package and market products for patient care; develop drug-delivery technologies; distribute pharmaceuticals, medical-surgical and laboratory supplies; and offer consulting and other services that improve quality and efficiency in health care. Headquartered in Dublin, Ohio, Cardinal Health employs more than 50,000 people on five continents and produces annual revenues of more than $44 billion. Cardinal Health is ranked #19 on the current Fortune 500 list and was named as one of “The World’s Best” companies by Forbes magazine in 2003.

[betterthantherest]

Hallo Mannerl,

wie findest du eigentlich deine Aktien?

Das KGV ist über 19 bei einem jährlichen Gewinnwachstum von 24% in den letzten 5 Jahren, bei steigender Tendenz.

Das price/book ratio ist 3,6. Mir gefallen Werte unter 1,5.

Das dept/equity ratio liegt bei 0,33. Das sehe ich als positiv.

Die profit margin erreicht nur 2,5%. Das heißt, dass viel Aufwand für nur wenig Gewinn notwendig ist.

Die Dividendenrendite beträg allem Anschein nach nur magere 0,2%, da kann man leicht die Dividende erhöhen.

Ich meine, dass diese Aktie in der nächsten Zeit nicht mehr so schnell steigen wird, wie in den vergangenen Jahren.

[Mannerl]

die sind ja nur auf langfristige Beobachtungslisten von mir!

mehr ist da nicht dahinter!

[Mannerl]

Deiner Meinung nach eine Schrottaktie?

[betterthantherest]

Mannerl,

wie ist sie den auf deine Beobachtungsliste gekommen?

Auf den ersten Blick würde ich auf keinen Fall Schrott sagen.

Die Gewinne sind in den letzten Jahren immer stärker gestiegen, das ist ja schon mal nicht schlecht.

Hast du dir schon mal Multex angesehen.
Dort gibt es auch das so genannte ratio comparision.

Der Wert wird mit der Indusrie usw. verglichen. Liegt besser als der Durchschnitt.

Es wäre interessant mit dem screening center Vergleiche mit anderen Unternehmen aus dieser Branche anzustellen.

Ich meine, dass die Branche zur Zeit recht hoch bewertet wird und wenn sich die Meinung wieder ändert, könnte hier längere Zeit tote Hose sein.

Siehe Chips oder Biotech.

[Mannerl]

das mit den Multex muss ich mir mal genauer ansehen!

...ist ja sicherlich nicht so dass wenn man ein Börsenkürzel eingibt (z. B. cah) dann ein Fenster erscheint ob die Aktie "gut" ist oder nciht!

...

Diese Aktie ist mir einfach so in den Schoß gefallen!

...

Genau so könntest Du einen Staranalyst fragen wieso er die DTE 2001 zum Kauf empfehlte!

...

meiner Meinung nach sind wir eh noch nicht übern Berg...wegen der Hochbewertugn wie Du sie angesprochen hast!
siehe auch

THREAD]701224[/THREAD]

von hinten lesen!

MFG
Mannerl, der trotzdem ab und zu auf diese Aktie schaut!

[betterthantherest]

Mannerl

meines Wissens sind an der NASDAQ um die 9000 Gesellschaften gelistet.

Da braucht man irgendwas um die Spreu vom Weizen zu trennen.

Mit dem screening kann man nach dem Ausschlußverfahren alles eliminieren was einem nicht gefällt.

Abzuwarten finde ich nicht verkehrt.

Wenn ich mir Charts so ansehe, meine ich, dass es die besten Kaufgelegenheiten in den Monaten September und Oktober gibt.

[Mannerl]

Cardinal Health Launches Newsletter for Investors


DUBLIN, Ohio, May 22, 2003 /PRNewswire-FirstCall via COMTEX/ -- Cardinal
Health, Inc. (NYSE: CAH), the leading provider of products and services
supporting the health care industry, today launched its first edition of The
Cardinal Health Investor, a periodic update designed to give investors and
analysts more insight into the issues and opportunities facing the company.

During the company`s annual analyst meeting in February 2003, Robert D. Walter,
chairman and chief executive officer, discussed the company`s long- term growth
outlook and plan to provide the investment community with information that
yields a better understanding of its strategy. The Cardinal Health Investor is
one of the ways the company is further enriching that information flow. From
time to time, The Cardinal Health Investor will also include data relating to
industry trends and other issues facing the markets in which the company
competes.

Today`s issue of The Cardinal Health Investor features operational highlights,
including a recap of the third quarter fiscal 2003 financial results, and a
reiteration of fourth quarter fiscal 2003 expectations, which include revenue
growth in the mid teens and operating earnings growth faster than revenue
growth, as well as interest and tax leverage driving 20 percent earnings growth.
A review of new and proprietary product offerings and answers to frequently
asked questions are also presented.

Please visit the Investor Relations page at Cardinal Health`s Web site (
www.cardinal.com ) for complete access to the first edition of The Cardinal
Health Investor.

ABOUT CARDINAL HEALTH

Cardinal Health, Inc. ( www.cardinal.com ) is the leading provider of products
and services supporting the health-care industry. Cardinal Health businesses
develop, manufacture, package and market products for patient care; develop
drug-delivery technologies; distribute pharmaceuticals, medical- surgical and
laboratory supplies; and offer consulting and other services that improve
quality and efficiency in health care. Headquartered in Dublin, Ohio, Cardinal
Health employs approximately 50,000 people on five continents and produces
annual revenues of more than $47 billion. Cardinal Health is ranked #19 on the
current Fortune 500 list and was named one of `The World`s Best` companies by
Forbes magazine in 2002.

[Mannerl]

--------------------------------------------------------------------------------
Cardinal Health Introduces Health Care`s First Patient Room Automated Dispensing System for Medications and Supplies Pyxis PatientStation(R) SN Improves Patient Safety and Nurse Workflow


SAN DIEGO, Jun 2, 2003 /PRNewswire-FirstCall via COMTEX/ -- Cardinal Health,
Inc. (NYSE: CAH), announced today that July will mark its inaugural installation
of Pyxis PatientStation SN, the health care industry`s first-ever patient room
automated dispensing system at Baptist Health South Florida. This product
combines dispensing, verification and administration technology for medications
and supplies at the bedside. By integrating the industry-leading automation
found in earlier Cardinal Health innovations such as Pyxis MedStation(R), Pyxis
SupplyStation(R) and Pyxis PatientStation(R), Pyxis PatientStation SN improves
nurse workflow and efficiency, increases medication safety and enhances patient
satisfaction. The company made the announcement and introduced the new
technology at the ASHP (American Society of Health-System Pharmacists) 2003
Summer Meeting in San Diego.

[Mannerl]

FAST provides Cardinal Health with its FAST Data Search solution

Jul 08, 2003 (NORDIC BUSINESS REPORT via COMTEX) -- Norwegian search solutions
provider Fast Search & Transfer ASA (FAST) has announced that provider of
healthcare industry products and services Cardinal Health Inc has purchased its
FAST Data Search solution.

The solution will be applied in Cardinal Health`s Pharmaceutical Technologies
and Services portal and CardinalMD e-commerce site for the physician`s office.

Cardinal Health is paying software licence, maintenance and professional service
fees to FAST.

[Mannerl]

Cardinal Health Board Of Directors Authorizes $1 Billion Share-Repurchase Program


DUBLIN, Ohio, Aug 1, 2003 /PRNewswire-FirstCall via COMTEX/ -- The board of
directors of Cardinal Health, Inc. (NYSE: CAH), the leading provider of products
and services supporting the health care industry, today authorized the purchase
by Cardinal Health of up to $1 billion of its common shares.

The share-repurchase authorization permits the company to repurchase common
shares pursuant to terms management deems appropriate and at such time as it may
designate. The company will hold any repurchased shares as treasury shares and
intends to use them for general corporate purposes, including acquisitions and
for issuance upon exercise of outstanding stock options.

"With the most diverse portfolio of healthcare businesses in the industry, we
are extremely optimistic about our future. In light of yesterday`s closing
price, the Board of Directors determined that repurchasing our shares is one of
the best investments we can make," said Robert D. Walter, chairman and chief
executive officer of Cardinal Health. "We expect to generate over $1 billion in
operating cash flow in fiscal 2004. Additionally, our net debt to total capital
position of only 11 percent at June 30, 2003 provides us with significant
financial flexibility to fund both this program as well as future growth
opportunities

[Mannerl]

Cardinal Health steigert Umsatz und Gewinn

Der Medikamentengroßhändler Cardinal Health Inc. erzielte im ersten Geschäftsquartal zum 30. September ein Umsatzwachstum von 16 Prozent. Die operativen Umsatzerlöse stiegen von 11,4 Mrd. Dollar im entsprechenden Vorjahresquartal auf nun 13,3 Mrd. Dollar.

Gleichzeitig kletterte der Betriebsgewinn um 12 Prozent von 467,5 Mio. in der Vorjahresperiode auf 522,4 Mio. Dollar. Der Nettogewinn verbesserte sich auf 328,6 Mio. Dollar oder 74 Cents je Aktie, nach einem Vorjahresgewinn von 288,3 Mio. Dollar bzw. 64 Cents pro Aktie. Das Ergebnis des fortlaufenden Geschäfts erhöhte sich im Vorjahresvergleich von 67 Cents auf 76 Cents je Aktie, während Analysten einen Anstieg auf 77 Cents geschätzt hatten.

Im weiteren Verlauf des Geschäftsjahres rechnet Cardinal mit einem deutlichen Umsatzwachstum. Für das Gesamtjahr wird ein Anstieg beim Gewinn je Aktie (EPS) von über 15 Prozent erwartet.

Bisher stiegen die Aktien in New York um 2,8 Prozent und notieren aktuell bei 57,56 Dollar.

[betterthantherest]

Die Gewinnentwicklung der letzten Jahre sieht wirklich gut aus.

Für meine Verhältnisse müsste nur noch die Aktie um ein gutes Stück billiger sein.

[Mannerl]

die Aktie der Firma hat auch einen ziemlichen Rutsch nach unten gemacht!

[Mannerl]

Jan 13, 2004 (streetinsider.com via COMTEX) -- Cardinal Health Inc. (NYSE: CAH)
backs mid-teens or higher EPS growth in 2004.

[Mannerl]

Schaeffer`s Option Activity Watch:

1. Cardinal Health (NYSE:CAH) is one of the largest United States distributor of
pharmaceuticals and other medical supplies and equipment. This Fortune 500
company has seen a rise in pessimism recently. The security`s Schaeffer`s
put/call open interest ratio (SOIR) spiked overnight from 1.12 to 1.36 and is
now higher than 70 percent of all those taken over the past year. This increase
was helped by the more than 3,800 contracts added to the stock`s March 65 put.
Open interest at this strike now checks in at 7,482 contracts. Meanwhile, short
interest dipped by 10 percent in January to 11.1 million shares. However, at
CAH`s average daily trading volume, it would still take more than four days to
cover these short positions. This hefty accumulation of bearish bets could lend
a hand of support to the shares. Wall Street has some lingering skepticism
toward the security as well, with nine of the 16 analysts following CAH rating
it a "hold." Any upgrades could lift the stock higher.

Technically speaking, CAH has underperformed the S&P 500 Index (SPX) since
October 2002. The equity is currently testing support at its 20-day moving
average. From a longer-term perspective, the stock has been slowly grinding
higher recently and has pulled its 10-month and 20-month moving averages into a
bullish cross. This technical formation often signals further strength for the
security. However, what has me concerned is that CAH continues to make a series
of lower monthly highs. I would be hesitant to jump on this stock until it
logged a higher monthly high.

[Mannerl]

Ligand and Cardinal Health Execute New Five-Year Agreement to Manufacture and Package AVINZA; Key Second Source of Supply for Ligand`s Largest Product


SAN DIEGO, Mar 3, 2004 (BUSINESS WIRE) -- Ligand Pharmaceuticals Incorporated
(Nasdaq: LGND) announced today it has entered into an agreement with Cardinal
Health PTS, LLC, a subsidiary of Cardinal Health Inc. (NYSE: CAH), for the
manufacturing and packaging of AVINZA(R) (morphine sulfate extended-release
capsules). Under a long-term contract, AVINZA will be manufactured at the
Cardinal Health facility located in Winchester, Kentucky. Ligand and Cardinal
Health have an existing relationship for the fill/finish of Targretin(R)
capsules.

Under the terms of the new agreement, upon the successful completion of
technology transfer and regulatory approval, manufacturing will commence for a
five-year term. Ligand has an option to extend for an additional two-year
period. During the interim, Ligand and Cardinal Health will work closely
together in the qualification and validation of the facility. Ligand and
Cardinal Health intend to file for regulatory approval in 2005. Financial terms
of the contract were not disclosed.